NIH-developed Epstein-Barr virus vaccine elicits potent neutralizing antibodies in animals

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators have developed an experimental, nanoparticle-based vaccine against Epstein-Barr virus (EBV) that can induce potent neutralizing antibodies in vaccinated mice and nonhuman primates. Microscopic particles, known as nanoparticles, are being investigated as potential delivery vehicles for vaccines. The scientists' findings suggest that using a structu...